Cargando…
A Pilot Study of 0.4% Povidone-Iodine Nasal Spray to Eradicate SARS-CoV-2 in the Nasopharynx
PURPOSE: This study aimed to evaluate the virucidal efficacy of 0.4% povidone-iodine (PVP-I) nasal spray against SARS-CoV-2 in the patients’ nasopharynx at 3 minutes and 4 hours after PVP-I exposure. PATIENTS AND METHODS: The study was an open-label, before and after design, single-arm pilot study o...
Autores principales: | Sirijatuphat, Rujipas, Leelarasamee, Amorn, Puangpet, Thanapat, Thitithanyanont, Arunee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790155/ https://www.ncbi.nlm.nih.gov/pubmed/36575672 http://dx.doi.org/10.2147/IDR.S391630 |
Ejemplares similares
-
Prevalence and factors associated with COVID-19 among healthcare workers at a university hospital in Thailand
por: Sirijatuphat, Rujipas, et al.
Publicado: (2022) -
Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial
por: Arefin, Mostafa Kamal, et al.
Publicado: (2021) -
Virucidal Effect of Povidone Iodine on SARS-CoV-2 in Nasopharynx: An Open-label Randomized Clinical Trial
por: Kamal Arefin, Mostafa, et al.
Publicado: (2022) -
Povidone iodine development
por: O’Sullivan, J.
Publicado: (2020) -
Intravitreal Injection of 1.25% Povidone Iodine Followed by Vitrectomy Using 0.025% Povidone Iodine Irrigation for Treating Endophthalmitis
por: Nakashizuka, Hiroyuki, et al.
Publicado: (2019)